Elanco's Credelio Quattro hits $100mln in net sales, fastest pet health blockbuster in history.

• Credelio Quattro reaches $100 million in net sales, Elanco's fastest pet health blockbuster • Credelio Quattro joins Experior as Elanco's second product to reach $100 million milestone • Zenrelia (ilunocitinib tablets) now in market in EU and Great Britain • Elanco's commitment to pet health innovations demonstrated through Credelio Quattro and Zenrelia • Elanco aims to help pet owners and veterinarians with standard treatment advancements.

Elanco Animal Health Incorporated (NYSE: ELAN) has announced a significant milestone with its pet health product Credelio Quattro, which has reached $100 million in net sales in less than eight months. This achievement makes Credelio Quattro Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval [1].

Credelio Quattro, a broad-spectrum parasite protection product, offers protection against fleas, ticks, heartworm disease, and three intestinal parasites. The product has captured approximately 14% of the dollar share in broad-spectrum sales out of U.S. veterinary clinics in June [1]. This success is attributed to its innovative formula, which includes lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets, providing comprehensive protection against a wide range of parasites.

The product's rapid success underscores Elanco's commitment to innovation and its ability to meet the growing demand for effective pet health solutions. Bobby Modi, Executive Vice President of U.S. Pet Health and Global Digital Transformation at Elanco, stated, "We're seeing incredibly strong demand for all-in-one products from pet owners and veterinarians alike. In fact, Credelio Quattro captured approximately 14% of the dollar share in broad-spectrum sales out of U.S. veterinary clinics in June" [2].

In addition to Credelio Quattro, Elanco has also launched Zenrelia, a once-daily oral JAK inhibitor for controlling itching associated with allergic and atopic dermatitis in dogs over 12 months. Zenrelia is now available in the European Union and Great Britain, following approvals in Brazil, Canada, Japan, and the United States [1]. The product has been well-received by veterinarians and pet owners, with more than half a million dogs treated with Zenrelia [1].

Elanco's success with Credelio Quattro and Zenrelia demonstrates its dedication to advancing the standard of treatment for pets. The company's global expansion plans for Credelio Quattro, with submissions made in Australia, Canada, the European Union, the United Kingdom, and Japan, are set to begin in 2026 [1]. This geographic expansion is expected to further cement Elanco's position as a leader in the pet health industry.

Elanco's financial performance has also been strong, with the company reporting its second-quarter 2025 earnings exceeding analysts' expectations. The company achieved an adjusted earnings per share of $0.26, compared to the projected $0.20, and revenue for the quarter reached $1.24 billion, exceeding the anticipated $1.18 billion [1]. Additionally, Elanco is set to join the S&P MidCap 400 index, replacing Sarepta Therapeutics, as part of a broader reshuffling involving several companies [1].

References:
[1] https://www.investing.com/news/company-news/elancos-credelio-quattro-hits-100-million-sales-milestone-93CH-4228553
[2] https://www.morningstar.com/news/pr-newswire/20250908de67421/elanco-innovation-builds-momentum-credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-reaches-blockbuster-status